ARQT Q1 2024 Earnings — Arcutis Biotherapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ARQTArcutis Biotherapeutics, Inc.

$3B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$50M+1682.4% YoY

Gross Profit

$46M93.4% margin

Operating Income

-$32M-63.8% margin

Net Income

-$35M-71.4% margin

EPS (Diluted)

$-0.32

QoQ Revenue Growth

+266.5%

Cash Flow

Operating Cash Flow

-$32M

Free Cash Flow

-$32M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$479M

Total Liabilities

$254M

Stockholders' Equity

$225M

Cash & Equivalents

$191M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$50M	$3M	+1682.4%
Gross Profit	$46M	$2M	+2218.0%
Operating Income	-$32M	-$76M	+58.5%
Net Income	-$35M	-$80M	+55.6%